XML 21 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
 3 Months Ended
Mar. 31, 2012
Operating Segment and Geographic Information [Abstract]  
Operating Segment And Geographic Information [Text Block]
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
Our chief operating decision-maker is our Chief Executive Officer, who regularly evaluates our performance based on net sales and gross profit. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be directionally correct, actual results could differ from the estimates and assumptions used in preparing this information.
The accounting policies of the segments are the same as the policies discussed in Footnote B – Summary of Significant Accounting Policies.
We have three reportable operating segments, Clinical Laboratories, Pharmacogenomic Services and Diagnostic Tools. During the third quarter of 2011, we changed the manner in which we report segment results internally. Accordingly, segment results of the prior period have been reclassified to reflect these changes. Beginning with the third quarter of 2011, our chief operating decision-maker reviews our business as having three segments. The change in segments was driven by our corporate strategy to advance personalized medicine through proprietary molecular technologies and world-class clinical and research services. These lines of business are complementary with the Pharmacogenomics Services driving innovation and leading to kit production in our Diagnostic Tools segment and new tests in our Clinical Laboratories.
 
Segment information for the three months ended March 31, 2012 and 2011 is as follows:
 
 
Dollars in Thousands
 
2012
 
Clinical Laboratories
 
Pharmacogenomic Services
 
Diagnostic
Tools
 
Total
Net Sales
$
3,371

 
$
630

 
$
3,205

 
$
7,206

Gross Profit
1,274

 
374

 
1,456

 
3,104

Net Income (Loss) before Taxes
(2,168
)
 
81

 
(605
)
 
(2,692
)
Income Tax Expense (Benefit)
—

 
—

 
4

 
4

Net Income (Loss)
$
(2,168
)
 
$
81

 
$
(609
)
 
$
(2,696
)
Depreciation/Amortization
416

 
32

 
47

 
495

Interest Income (Expense)
(247
)
 
(5
)
 
(21
)
 
(273
)
 
 
 
 
 
 
 
 
 
March 31, 2012
Total Assets
27,118

 
3,477

 
16,589

 
47,184


 
 
 
 
 
 
 
 
 
Dollars in Thousands
 
2011
 
Clinical Laboratories
 
Pharmacogenomic Services
 
Diagnostic
Tools
 
Total
Net Sales
$
3,487

 
$
270

 
$
3,723

 
$
7,480

Gross Profit
1,900

 
(113
)
 
2,367

 
4,154

Net Loss before Taxes
(3,289
)
 
(247
)
 
752

 
(2,784
)
Income Tax Expense (Benefit)
—

 
—

 
(6
)
 
(6
)
Net Loss
$
(3,289
)
 
$
(247
)
 
$
758

 
$
(2,778
)
Depreciation/Amortization
394

 
34

 
49

 
477

Restructure
—

 
—

 
24

 
24

Interest Income (Expense)
(233
)
 
—

 
(5
)
 
(238
)
 
 
 
 
 
 
 
 
 
March 31, 2011
Total Assets
19,853

 
1,964

 
9,581

 
31,398


 
Net sales for the three months ended March 31, 2012 and 2011 by country were as follows:
 
 
Dollars in Thousands
 
Three Months Ended
 
March 31,
 
2012
 
2011
United States
$
4,724

 
$
5,036

Italy
799

 
826

United Kingdom
336

 
258

All Other Countries
1,347

 
1,360

Total
$
7,206

 
$
7,480

No other country individually accounted for more than 5% of total net sales.

More than 95% of our long-lived assets are located within the United States. Substantially all of the remaining long-lived assets are located within Europe.